We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain MEDNAX (MD) in Your Portfolio
Read MoreHide Full Article
MEDNAX Inc. (MD - Free Report) has been in investors’ good books owing to its strategic acquisitions and an increasing top line on the back of operational efficiency along with solid segments. Its booming telehealth services are another positive.
Over the past 30 days, the stock has witnessed its 2021 and 2022 earnings estimates move 0.7% and 1.2% north, respectively.
The company has been gaining from its strong patient volume trends. On its last earnings call, management said that patient volumes across all services exceeded the pre-pandemic levels. MEDNAX is continuing to add various specialties to its portfolio, such as neurology, endocrinology, gastroenterology, hematology, etc.
It has a Value Score of A, reflecting its attractive stock value.
Now let’s see why this currently Zacks Rank #3 (Hold) player is an investor favorite now.
The company has an active inorganic growth profile. It acquires companies and forges alliances to enhance its capabilities. In 2019, it closed the buyouts of nine physician group practices including two neonatology physician practices, two maternal-fetal physician practices, one radiology practice and four other pediatric subspecialty practices. In 2020, it bought one paediatric subspecialty practice for $2.1 million. The company has a solid pipeline of activities coming up.
MEDNAX divested its MedData business to Frazier Healthcare Partners in 2019, which helped it focus on its core business. Following its MedData transaction, the company is now an organization dedicated to physician services and patient care. Moreover, it sold American Anesthesiology, which helped it mitigate cash losses induced by the coronavirus outbreak as well as lower its risk profile. MEDNAX also sold MEDNAX Radiology Solutions to focus on its core pediatrics and obstetrics business lines. All these enabled it to streamline its business.
The hospital company is expanding its telehealth services to ensure access to healthcare even from the confines of one’s residence. Given the current scenario, demand for virtual medical care services is here to stay, which will allow the company to bolster its telehealth service business line.
The company has been witnessing a healthy revenue stream on the back of its operational excellence, inorganic growth via strategic acquisitions and strong segmental performances for a while now. This is evident from its CAGR of 6% witnessed during the 2015-2019 period. In the first six months, revenues skyrocketed 213.2% year over year owing to robust volumes. We expect the company to continue witnessing top-line growth on the back of its strategic measures.
The company’s long-term growth rate stands at 19.5%, higher than the industry's average of 11.7%.
Shares of Mednax have surged 85.2% in a year compared with the industry’s rally of 105.8%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks in the same space are Universal Health Services, Inc. (UHS - Free Report) , Tenet Healthcare Corporation (THC - Free Report) and HCA Healthcare, Inc. (HCA - Free Report) , each carrying a Zacks Rank #2 (Buy), currently.
Image: Bigstock
Here's Why You Should Retain MEDNAX (MD) in Your Portfolio
MEDNAX Inc. (MD - Free Report) has been in investors’ good books owing to its strategic acquisitions and an increasing top line on the back of operational efficiency along with solid segments. Its booming telehealth services are another positive.
Over the past 30 days, the stock has witnessed its 2021 and 2022 earnings estimates move 0.7% and 1.2% north, respectively.
The company has been gaining from its strong patient volume trends. On its last earnings call, management said that patient volumes across all services exceeded the pre-pandemic levels. MEDNAX is continuing to add various specialties to its portfolio, such as neurology, endocrinology, gastroenterology, hematology, etc.
It has a Value Score of A, reflecting its attractive stock value.
Now let’s see why this currently Zacks Rank #3 (Hold) player is an investor favorite now.
The company has an active inorganic growth profile. It acquires companies and forges alliances to enhance its capabilities. In 2019, it closed the buyouts of nine physician group practices including two neonatology physician practices, two maternal-fetal physician practices, one radiology practice and four other pediatric subspecialty practices. In 2020, it bought one paediatric subspecialty practice for $2.1 million. The company has a solid pipeline of activities coming up.
MEDNAX divested its MedData business to Frazier Healthcare Partners in 2019, which helped it focus on its core business. Following its MedData transaction, the company is now an organization dedicated to physician services and patient care. Moreover, it sold American Anesthesiology, which helped it mitigate cash losses induced by the coronavirus outbreak as well as lower its risk profile. MEDNAX also sold MEDNAX Radiology Solutions to focus on its core pediatrics and obstetrics business lines. All these enabled it to streamline its business.
The hospital company is expanding its telehealth services to ensure access to healthcare even from the confines of one’s residence. Given the current scenario, demand for virtual medical care services is here to stay, which will allow the company to bolster its telehealth service business line.
The company has been witnessing a healthy revenue stream on the back of its operational excellence, inorganic growth via strategic acquisitions and strong segmental performances for a while now. This is evident from its CAGR of 6% witnessed during the 2015-2019 period. In the first six months, revenues skyrocketed 213.2% year over year owing to robust volumes. We expect the company to continue witnessing top-line growth on the back of its strategic measures.
The company’s long-term growth rate stands at 19.5%, higher than the industry's average of 11.7%.
Shares of Mednax have surged 85.2% in a year compared with the industry’s rally of 105.8%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks in the same space are Universal Health Services, Inc. (UHS - Free Report) , Tenet Healthcare Corporation (THC - Free Report) and HCA Healthcare, Inc. (HCA - Free Report) , each carrying a Zacks Rank #2 (Buy), currently.
Earnings of Universal Health, Tenet Healthcare and HCA Healthcare managed to deliver a trailing four-quarter surprise of 29.01%, 61.03% and 11.65%, respectively, on average. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.